Corcept Therapeutics (CORT) Tops Q2 EPS by 2c; Offers FY22 Revenue Guidance

Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.24, $0.02 better than the analyst estimate of $0.22. Revenue for the quarter came in at $103.4 million versus the consensus estimate of $100.62 million.

GUIDANCE:

Corcept Therapeutics sees FY2022 revenue of $400-430 million, versus the consensus of $414.4 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.

You May Also Be Interested In

• HP Inc. projects mid-single-digit PC market decline in 2027
• Deutsche Bank Reiterates Buy Rating on Volkswagen AG (VOW:GR) (VWAGY)
• Westinghouse said to seek over $50 billion valuation in planned IPO